Bevacizumab Improves PFS, But Not OS, When Combined With Chemotherapy in SCCHN
Bevacizumab added to a standard platinum doublet chemotherapy regimen did not improve OS, though PFS was improved, among patients with cancer of the head and neck.
ASCO 2017
Intermittent Letrozole May Benefit Some Patients With Breast Cancer
Study data suggest that some women with breast cancer may benefit from intermittent over continuous letrozole treatment.
FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer
Perioperative FLOT significantly improved PFS and OS among patients with resectable gastric cancers compared with standard ECF/ECX.
Pembrolizumab Active in Advanced Gastric Cancer
Pembrolizumab monotherapy showed clinical efficacy in patients with advanced gastric cancer.
High Activity for Nivolumab Alone and With Ipilimumab in Small-cell Lung Cancer
Nivolumab alone or combined with ipilimumab provided durable responses in patients with advanced small-cell lung cancer whose disease progressed on prior platinum therapies.
Momelotinib for Previously Treated Patients With Myelofibrosis
For patients with primary or secondary myelofibrosis who have already received ruxolitinib, momelotinib was significant in improving disease-related symptoms over best available therapy.
Dabrafenib Plus Trametinib Promising in Melanoma
Patients with BRAF V600E melanoma and brain metastasis showed intracranial responses when receiving a BRAF (dabrafenib) and a MEK inhibitor (trametinib).
Adding Veliparib to Doublet Chemotherapy Improves PFS in Small-cell Lung Cancer
Veliparib added to cisplatin and etoposide improves progression-free survival among patients with extensive stage small-cell lung cancer.
Three-month XELOX Regimen May Be Non-inferior to 6-month Regimen in Colorectal Cancer
An analysis suggested that a shorter, 3-month course of adjuvant chemotherapy for some patients with stage III colon cancer may yield comparable outcomes to the standard 6-month course.
Olaparib is Efficacious in BRCA-related Metastatic Breast Cancer
Patients with a germline BRCA mutation were at a reduced risk for progression when treated with olaparib for HER2-metastatic breast cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2017
Loading... 
Loading...